Roles of 17β-hydroxysteroid dehydrogenase type 10 in neurodegenerative disorders  by Yang, Song-Yu et al.
Review
Roles of 17b-hydroxysteroid dehydrogenase type 10 in
neurodegenerative disorders
Song-Yu Yang a,e,*, Xue-Ying He a, Charles Isaacs a, Carl Dobkin b,e,
David Miller c, Manfred Philipp d,f
aDepartment of Developmental Biochemistry, NYS Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314,
USA
bDepartment of Molecular Genetics, NYS Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314, USA
cDepartment of Molecular Biology, NYS Institute for Basic Research in Developmental Disabilities, 1050 Forest Hill Road, Staten Island, NY 10314, USA
dDepartment of Chemistry, Lehman College of CUNY, 250 Bedford Park Boulevard West, Bronx, NY 10468, USA
eNeuroscience Doctoral Program, Graduate Center of the City University of New York, 365 Fifth Avenue, NY 10016, USA
f Biochemistry Doctoral Program, Graduate Center of the City University of New York, 365 Fifth Avenue, NY 10016, USA
A R T I C L E I N F O
Article history:
Received 29 April 2014
Received in revised form 2 July 2014
Accepted 3 July 2014











A B S T R A C T
17b-Hydroxysteroid dehydrogenase type 10 (17b-HSD10) is encoded by the HSD17B10 gene mapping at
Xp11.2. This homotetrameric mitochondrial multifunctional enzyme catalyzes the oxidation of
neuroactive steroids and the degradation of isoleucine. This enzyme is capable of binding to other
peptides, such as estrogen receptor a, amyloid-b, and tRNA methyltransferase 10C. Missense mutations
of the HSD17B10 gene result in 17b-HSD10 deﬁciency, an infantile neurodegeneration characterized by
progressive psychomotor regression and alteration of mitochondria morphology. 17b-HSD10 exhibits
only a negligible alcohol dehydrogenase activity, and is not localized in the endoplasmic reticulum or
plasma membrane. Its alternate name – Ab binding alcohol dehydrogenase (ABAD) – is a misnomer
predicated on the mistaken belief that this enzyme is an alcohol dehydrogenase. Misconceptions about
the localization and function of 17b-HSD10 abound. 17b-HSD10's proven location and function must be
accurately identiﬁed to properly assess this enzyme’s important role in brain metabolism, especially the
metabolism of allopregnanolone.
The brains of individuals with Alzheimer’s disease (AD) and of animals in an AD mouse model exhibit
abnormally elevated levels of 17b-HSD10. Abnormal expression, as well as mutations of the HSD17B10
gene leads to impairment of the structure, function, and dynamics of mitochondria. This may underlie the
pathogenesis of the synaptic and neuronal deﬁciency exhibited in 17b-HSD10 related diseases, including
17b-HSD10 deﬁciency and AD. Restoration of steroid homeostasis could be achieved by the
supplementation of neuroactive steroids with a proper dosing and treatment regimen or by the
adjustment of 17b-HSD10 activity to protect neurons. The discovery of this enzyme's true function has
opened a new therapeutic avenue for treating AD.
ã 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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1. Introduction
Human 17b-hydroxysteroid dehydrogenase type 10 is a
multifunctional protein encoded by the HSD17B10 (formerly
HADH2) gene (OMIM300256) [1]. Human HSD10 cDNA was cloned
from brain (NM_004493), and the resulting protein, a homote-
tramer [2,3] (Fig. 1), was ﬁrst characterized as a short chain 3-
hydroxyacyl-CoA dehydrogenase (SCHAD) [2,4,5]. Active sites of
this enzyme can accommodate different substrates; 17b-HSD10 is
involved in the oxidation of isoleucine, branched-chain fatty acids,
and xenobiotics as well as the metabolism of sex hormones and
neuroactive steroids (Table 1) [1–15].
17b-HSD10 is the sole 17b-hydroxysteroid dehydrogenase, out
of 14 different types, that is localized in the mitochondria [16,17].
Ever since the role of this mitochondrial enzyme in the metabolism
of steroid hormones and neuroactive steroids was recognized
[4,5,15], it has been designated as 17b-hydroxysteroid dehydroge-
nase type 10 (17b-HSD10) [18,19]. This enzyme also can form
complexes with other proteins to generate mtRNase P activity [20].
When 17b-HSD10 binds to estrogen receptor alpha or amyloid
b-peptides, various 17b-HSD10 functions are inhibited [21,22]. The
molecular weight of 17b-HSD10/SCHAD that is composed of four
identical subunits is 108 kDa; each subunit consists of 261 amino
acid residues [2]. Although the endoplasmic reticulum-associated
amyloid-b peptide binding protein (ERAB) was reported to be
associated with the ER and to consist of 262 residues with a
molecular weight of 27 kDa [23,24], ERAB is actually identical to
17b-HSD10/SCHAD [2] that is localized in mitochondria but not ER
[4,5,15,18,19]. In experimental animals, rat 17b-HSD10 and mouse
17b-HSD10 encoded by the rat Hsd17b10 gene and the mouse
Hsd17b10 gene, respectively, are also localized in the mitochondria
[25,26]. Nevertheless, generalized alcohol dehydrogenase activity
and triple intracellular localization was attributed to ERAB by
publishing artifacts. On the basis of such misconceptions, ERAB
[6,23] was renamed Ab-binding alcohol dehydrogenase (ABAD)
[6,27]. Later reports claimed that ABAD concentrates in mitochon-
dria [28], yet made no reference to published characterizations of
17b-HSD10/SCHAD [2,4,5,15,18,19].
2. 17b-HSD10 deﬁciency – a progressive infantile
neurodegeneration
2.1. Mutation hotspot
The HSD17B10 gene maps to a chromosomal region closely
associated with X-linked mental disorders [29]. In addition to its
enzymatic activities, the capability of 17b-HSD10 to bind to
various peptides also is believed to play an important role in
human health and disease [30]. Missense mutations in the
HSD17B10 gene result in a progressive infantile neurodegeneration
[31], namely 17b-HSD10 deﬁciency (OMIM#300438). About 50%
of such cases are caused by a c.388C>T transition due to a 5-
methylcytosine hotspot, which was identiﬁed at the +2259
nucleotide from the initiation codon ATG of the HSD17B10 gene
[32].
2.2. Mimics a mitochondrial disease
Individuals with 17b-HSD10 deﬁciency may have microcephaly
but no dysmorphism or organomegaly. One of the predominant
clinical features of this disease is psychomotor regression whose
onset often occurs at 6–36 months after birth [8,30–38].
Mimicking a mitochondrial disease [37], the cells of 17b-HSD10
deﬁcient patients exhibit mitochondrial morphology that is
severely altered such that the majority of mitochondria appear
to be rounded with depleted cristae [38].
Fig. 1. Ribbon representation of human 17b-HSD10 in complex with cofactor NAD
+ and inhibitor AG18051. The tetramer is viewed down one of three mutually
perpendicular 2-fold axes. Individual subunits are shown in red, green, blue and
yellow. The bound NAD+ and suicide inhibitor are shown in ball-and-stick
representations. White arrows indicate the D loop close to the viewer. (Adapted
from Fig. 3 of [3]).
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2.3. Clinical hallmark – a blockade of isoleucine degradation
Because 17b-HSD10 (formerly SCHAD [1,7,8,10] is a key
enzyme in the isoleucine oxidation pathway (Fig. 2), all
individuals with 17b-HSD10 deﬁciency have a blockade of
isoleucine degradation [8,34,39]. Some patients who have a mild
mental disability have normal levels of isoleucine metabolites in
the blood because they carry a silent mutation, c.574C>A, in the
HSD17B10 gene [40]. They suffer from X-linked mental disabilities,
choreoathetosis and abnormal behavior (MRXS10) [41]
(OMIM#300220) – but not 17b-HSD10 deﬁciency. In some
individuals with 17b-HSD10 deﬁciency, one biochemical ﬁnding
of mitochondrial dysfunction is an increase in lactate levels [42].
No signs of abnormal ketone body metabolism are exhibited, and
the oxidation of D-3-hydroxybutyrate catalyzed by 17b-HSD10, if
any [27], is insigniﬁcant (Table 1). Although elevated levels of
isoleucine metabolites in blood and their excretion in urine are a
clinical hallmark of 17b-HSD10 deﬁciency, the accumulation of
tiglylglycine and 2-methyl-3-hydroxybutyrate is perhaps only a
pathophysiological background of this disease; an imbalance in
neurosteroid metabolism could be a major cause of the observed
neurological handicap [8].
A low-protein, high-energy dietary regimen with carnitine
supplementation reduces the accumulation of isoleucine metab-
olites in blood and urine (Fig. 3), but it cannot ameliorate the
patients’ psychomotor regression [31–33].
2.4. Metabolism of allopregnanolone
Allopregnanolone (ALLOP) is a potent, positive allosteric
modulator of GABAA receptors, and has a signiﬁcant impact on
the GABAA receptor plasticity [43–45]. ALLOP can be de novo
synthesized in the central nervous system by the reduction of
progesterone to 5a-dihydroprogesterone (5a-DHP) under the
catalysis of 5a-reductase. 5a-DHP has no effect on GABAA
receptors, but it can be further reduced to ALLOP by the oxidation
of NADPH under the catalysis of 3a-hydroxysteroid dehydrogenase
type 3 (3a-HSD3) [46]. Since the ratio of NADPH/NADP+ is much
greater than 10 in the cytosol [47] and since 3a-hydroxysteroid
dehydrogenase type 3 (AKR1C2) itself prefers to form an ENADPH
binary complex, 3a-HSD3 acts predominantly as a 17-ketosteroid
reductase (AKR1C2) to generate ALLOP. As a result, any serious
discussion of the metabolism of ALLOP has to include a reliable
mechanism that could effectively inactivate ALLOP.
It was reported [12,48] that mitochondrial 17b-HSD10, but not
3a-HSD3 (AKR1C2), should be responsible for the catalysis of the
oxidative inactivation of ALLOP. Since NAD+ is the coenzyme of
17b-HSD10 that is localized in mitochondria where the ratio of
NADH/NAD+ is about 0.1, ALLOP is converted back to 5a-DHP in
mitochondria. Two distinct enzymes, i.e., 3a-HSD3 (AKR1C2) and
17b-HSD10, in two different compartments have a part to play in
the metabolism of ALLOP (Fig. 4).
When neuronal progenitors migrate from the ventricular zone
to the cortical plate region they become predominantly GABAergic
[49]. A normal level of wild type 17b-HSD10 is, therefore, essential
for brain development and cognitive function. The imbalance of
neuroactive steroid metabolism, especially ALLOP metabolism, in
brains of individuals with 17b-HSD10 deﬁciency remains to be
studied. Such investigations would lay a foundation for the
effective treatment of this kind of developmental intellectual
disabilities.
2.5. Ab undetectable in patient's cerebrospinal ﬂuid
Whether the amyloid-b peptide is involved in the infantile
neurodegeneration of 17b-HSD10 deﬁciency is of great interest. It
was recently reported [50] that Ab peptide is undetectable in the
cerebrospinal ﬂuid (CSF) of an individual with 17b-HSD10
deﬁciency. If this observation is conﬁrmed in other affected
individuals, the implication would be that a missense mutation in
the HSD17B10 gene could alter the metabolism or trafﬁcking of the
amyloid precursor protein (APP) [51]. Because APP is a known risk
factor for AD, studies on 17b-HSD10 deﬁciency may lead to new
avenues for the treatment of AD.
3. Misconceptions in 17b-HSD10 research
3.1. Is Ab-binding alcohol dehydrogenase really an alcohol
dehydrogenase?
3.1.1. The myth of generalized alcohol dehydrogenase activity
Literature references to Ab-binding alcohol dehydrogenase
(ABAD) as a recharacterization of ERAB [6,27,28] – itself a
misnomer for 17b-HSD10 – do not account for the establishment
of 17b-HSD10/SCHAD as a mitochondrial hydroxysteroid dehy-
drogenase [2–5,11,15,18,19]. The ABAD designation relied on a
reported generalized alcohol dehydrogenase activity that pur-
portedly catalyzed the oxidation of a variety of aliphatic alcohols
in which the alkyl groups range from n-decanol (C10) to ethanol
(C2). According to the published Experimental Procedure section
of the key reference that attempted to establish ERAB as ABAD, the
“[a]lcohol dehydrogenase assays employed ERAB/HADHII (20 mg/
ml), a range of alcohol substrates and concentrations (methanol,
ethanol, n-propanol, isopropanol, n-butanol, ()-2-octanol, (+)-2-
Table 1
Catalytic properties of human 17b-hydroxysteroid dehydrogenase type 10.
Substrate Product Km(mM) kcat(min1) kcat/Km(min1mM1) Ref
Acetoacetyl-CoA 3-Hydroxy-butyryl-CoA 89  5.4 2,220  96 24,943.80 [2]
2-Methyl-3-hydroxybutyryl- CoA 2-Methylacetoacetyl-CoA 7.1  1.1 398.96  37.74 56,191.50 [8]
Methanol Formaldehyde – Not detectable – [6]
Ethanol aldehyde – Not detectablea – [5]
2-Propanol Acetone 280,000  33,000 2.16  0.14 0.0077 [5]
Butanol Butyl aldehyde 43,500  8,300 0.50  0.03 0.011 [9]
D-3-hydroxy-butyrate Acetoacetate 4,500  1,000 0.11  0.001 0.024 [9]
17b-Estradiol Estrone 43.0  2.1 0.66  0.01 15.3 [4,5,11]
Allopregnanolone 5a-Dihydroprogesterone 15.0  1.7 6.40  0.20 426.7 [12]
Allotetrahydrodeoxycorticosterone 5a-Dihydrodeoxycorticosterone 9.7  1.3 13.40  0.70 1,381.0 [12]
3a-androstanediol 5a-Dihydrotestosterone 34.0  2.4 5.58  0.17 164 [5,11,15]
5a-Dihydrotestosterone 3a-androstanediol 112.0  18 1.94  0.21 17.3 [11,15]
Androsterone Androstanedione 45.0  9.3 0.66  0.08 14.7 [5,15]
Androstanedione Androsterone 44.0  2.5 0.23  0.01 5.2 [15]
a The absorbance change (DA340) is within the instrumental error range of the UV spectrophotometer when 7% alcohol solution was used as substrate in the alcohol
dehydrogenase assay. This alcohol concentration is about 100 times higher than the DWI (driving while intoxicated) limit.
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octanol, ()-2-octanol, and n-decanol; Sigma), and NAD+ (7.5 mM)
in 22 mM sodium pyrophosphate, 0.3 mM sodium phosphate (pH
8.8). The reaction was run for 2 h at 25 C, and the absorbance at
340 nm was monitored every 5 min as described above.” [6]. These
conditions raise very serious concerns about the reliability of the
results as described below.
As is well known, n-decanol and 2-octanol are immiscible with
water. For example, the saturating concentration of 2-octanol is no
more than 7 mM [52]; immiscibility has no exceptions among
enantiomers: ()-2-octanol, (+)-2-octanol, or ()-2-octanol.
160 mM or even 210 mM ()-2-octanol was reportedly used as
substrates for the alcohol dehydrogenase assays [6] (Fig. 5).
Fig. 2. Inborn errors in isoleucine metabolism. Dashed line boxes indicate the compounds excreted in the urine of 17b-HSD10 deﬁciency patients. A minor R pathway of
isoleucine oxidation where the breakdown of 2-ethylhydracrylic acid is very slow [104] is not shown here. BCKD, branched-chain a-keto acid dehydrogenase; DBT,
dihydrolipoamide branched-chain transacylase; DLD, dihydrolipoamide dehydrogenase; SBCAD, short branched-chain acyl-CoA dehydrogenase; b-KT, b-ketothiolase;
ACAT1, acetyl-CoA acetyltransferase 1. (Adapted from Fig. 1 of [39]).
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Because no solubilization method was ever reported, it is not
possible to reproduce the assays that purportedly establish ERAB/
ABAD's generalized alcohol dehydrogenase activity. In addition,
the catalytic rates of ABAD/ERAB reported for other substrates,
such as 17b-estradiol and acetoacetyl-CoA, appear to have been
exaggerated by three orders of magnitude and by ﬁve-fold,
respectively [5].
3.1.2. Negligible alcohol dehydrogenase activity of 17b-HSD10
Although ethanol is an alcohol miscible with water, the reported
turnover rate (kcat) catalyzed by ABAD/ERAB was 0.5 per second
when a 1.21 M ethanol solution was used as substrate [6]. The
catalytic efﬁciencies of this dehydrogenase (kcat/Km) reported for
aliphatic alcohols, e.g., ethanol (0.05 min1mM1) [6], 2-propanol
or “n-isopropanol” as stated in ref. 27 (0.01 min1mM1) [5] and n-
butanol (0.01 min1mM1) [9] are negligible, as compared with
those for steroids such as allopregnanolone (432 min1mM1) and
allotetrahydrodeoxycorticosterone (1381 min1mM1) [12].
Therefore, these data establish that it is perfectly proper to
designate this mitochondrial enzyme 17b-hydroxysteroid dehy-
drogenase type 10 [4,18,19], which is encoded by the human
HSD17B10 gene, as designated by the Human Gene Nomenclature
Committee (HGNC) [53].
Nonetheless, it was reported [6] that “the combination of Ab
binding properties and generalized alcohol dehydrogenase
activity, in addition to HADH activity, lead us to propose the
new name Ab binding alcohol dehydrogenase or ABAD to better
describe the unusual properties of the enzyme previously
referred to as ERAB or HADH II”. This statement conﬂicts with
the facts about 17b-HSD10. Although 17b-HSD10 is known to
have an afﬁnity for other peptides, including Ab [30], it exhibits
only a negligible alcohol dehydrogenase activity (Table 1). The
aim of this review is to dispel the mischaracterization of the
generalized alcohol dehydrogenase activity of ABAD/ERAB. Only
then can the research on this important brain enzyme 17b-HSD10
move forward.
Fig. 3. Changes of isoleucine metabolite levels in 17b-HSD10 deﬁciency patient's urine due to the low-protein dietary regimen. Urine organic acids were analyzed as
trimethylsilyl (TMS)-derivatives by gas chromatography-mass spectrometry. Urine organic acid proﬁles: (A) normal control; (B) 17b-HSD10 deﬁciency patient; (C) 17b-
HSD10 deﬁciency patient under low protein dietary regimen. 2MHBA, 2-methyl-3-hydroxybutyrate; EHA, 2-ethylhydracrylic acid; TG, tiglylglycine; IS, internal standard.
(Adapted from Fig. 1 of [33]).
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Fig. 4. Roles of brain 17b-HSD10 in the metabolism of allopregnanolone (ALLOP). ALLOP is a positive steroid modulator of GABAA receptors that potentiates GABA to increase
the opening of Cl channels. ALLOP is generated from 5a-dihydroprogesterone (DHP) by cytosolic 3a-HSD3 catalysis, whereas ALLOP is oxidized to 5a-DHP that has no effect
on GABAA receptors by the catalysis of mitochondrial 17b-HSD10 with the concomitant reduction of NAD+. — indicates the binding sites of individual modulators on the
GABAA receptor. (Adapted from Fig. 4 of [48] and the cover page of Neuropharmacology).
Fig. 5. Kinetic analysis of the endoplasmic reticulum-associated Ab-binding protein/Ab-binding alcohol dehydrogenase (17b-HSD10) activity and its inhibition by Ab. The
“mutERAB” represents a mutant 17b-HSD10 carrying Y168G/K172G mutations. (The upper part and bottom part were adapted from Fig. 2 and Fig. 5 of [6], respectively).
S.-Y. Yang et al. / Journal of Steroid Biochemistry & Molecular Biology 143 (2014) 460–472 465
3.1.3. Invalid competitive inhibition constants (Ki) of Ab
Further confusion concerning 17b-HSD10 was engendered by
reports of kinetic studies of ABAD/ERAB. 17b-HSD10 is inhibited by
the binding of estrogen receptor alpha [21] or Ab peptides that
include residues 12–24 [22]. The inhibition of 17b-HSD10 activities
by Ab reportedly follows a one-site model for competitive
inhibition [6], for which a well-known enzyme kinetics book
[54] had been cited as the speciﬁc reference. However, only a
single, ﬁxed substrate concentration was used to study the
competitive inhibition of ABAD/ERAB, which is inadequate to
establish the competitive inhibition. More surprisingly, competi-
tive inhibition constants (Ki) of Ab were reportedly obtained by
ﬁtting data to a one-site model for competitive inhibition (Fig. 5
bottom part A, B, and C). In fact, no such “one-site model for
competitive inhibition” is described in the cited reference [54].
Thus, it seems unlikely that any of the Ki values of Ab reported for
ABAD/ERAB [6,55,56] would be valid. The one-site competitive
inhibition model is another misconception that has emerged from
ABAD/ERAB studies [6,27,28]. The validity of ABAD/ERAB reports in
AD research [55–63] needs to be reexamined.
3.2. Does 17b-HSD10 have triple intracellular localization?
ERAB, a misnomer of 17b-HSD10, was reportedly localized in
ER, and would migrate to the plasma membrane after cells are
incubated with Ab peptides [23] (Fig. 6). However, the reported
migration of 17b-HSD10 from ER to plasma membrane [23,24] is
not reproducible except those shown in Fig. 6 of [6], because 17b-
HSD10 is, indeed, localized in mitochondria but not ER according to
honest immunocytochemical studies (Fig. 7) [4,15].
3.2.1. Conﬁrmation of erroneous data by distorted subcellular
fractionation
The localization of 17b-HSD10 in the mitochondria, ER, and
plasma membrane has been conﬁrmed by subcellular fraction-
ation data [6,27]. The fractionation experimental procedure
employed in ABAD/ERAB studies was reportedly described in a
particular reference [64]. Unfortunately, there is only half of a
sentence relevant to the fractionation experimental procedure,
i.e., "[f]ractionation of cell lysates was performed as described
(24), . . . .". As a matter of fact, the actually employed procedure
[6,27] has nothing to do with the subcellular fractionation
described in the indirectly cited literature [65], the purpose of
which is to isolate nuclei for the puriﬁcation of a transcription
factor [65]. If the conventional method instead of the distorted
subcellular fractionation procedure was performed, 17b-HSD10
cannot be detected in the ER fraction (Fig. 8). Data from the
honest immunocytochemical studies were perfectly corroborated
by data obtained from the conventional subcellular fractionation
experiments, because 17b-HSD10 possesses a non-cleavable
Fig. 6. Proposed intracellular localization of the endoplasmic reticulum-associated Ab-binding protein (17b-HSD10) and its redistribution to the plasma membrane.
(Adapted from Fig. 4 of [23]).
466 S.-Y. Yang et al. / Journal of Steroid Biochemistry & Molecular Biology 143 (2014) 460–472
mitochondrial targeting signal at its N-terminus (residues 1–11)
[15,18,19].
3.2.2. Cytochrome C used as the mitochondrial marker
As indicated by Nobel laureate Christian de Duve, cytochrome C
is readily released from damaged mitochondria. The use of
cytochrome C rather than cytochrome C oxidase as a marker for
mitochondria in ABAD/ERAB studies [6,27] resulted in additional
artifacts [18] that further promoted ABAD/ERAB's erroneous and
astonishing story.
Misconceptions that emerged from ABAD/ERAB studies have
severely impacted 17b-HSD10 research. It is hoped that in the
future, erroneous triple intracellular localization of 17b-HSD10 in
public databases (Supplementary Materials S1) based upon reports
that are not supported by any reliable data, will be corrected, and
that the underlying reports [6,23,24,27,28] will be withdrawn.
4. Signiﬁcance of 17b-HSD10 for Alzheimer's disease (AD)
4.1. Elevated levels of 17b-HSD10 in AD brains
The 17b-HSD10 sequence and the coding nucleotide sequence
of the HSD17B10 gene are highly conserved among animals and
appear to be indispensable for life [66,67]. 17b-HSD10 is present in
brain regions at different levels, and is most abundant in the
hippocampus [48]. 17b-HSD10 concentrations in the CSF may
reﬂect its quantity in the brain. It was reported [68] that 17b-
HSD10 concentration in the CSF declines with age, yet there is 5.7-
fold more 17b-HSD10 in AD patients' CSF than in corresponding
age-matched controls. Furthermore, abundant 17b-HSD10 is
found in the brains of AD patients [48] as well as of an AD mouse
model [26] (Fig. 9). It has been reported [11] that overexpression of
17b-HSD10 results in mitochondrial matrix condensation and
partial loss of cristae structure.
4.2. Oligomeric Ab bound to 17b-HSD10
The D loop of 17b-HSD10 has a short b hairpin structure and
extends the subunit interface in the homotetramer by contacting
the helix aE2 of an adjacent monomer (Fig. 1). A unique insertion I
region of the D loop can bind Ab [3]. The dissociation constant of
Fig. 7. Intracellular localization of 17b-HSD10 expressed in COS-7 cells. All cells either transfected with a 17b-HSD10 expression vector (D–F) or a control vector (A–C) were
immunostained with the primary anti-17b-HSD10/SCHAD antibody and then with the ﬂuorescence-tagged secondary antibody, and 17b-HSD10 is shown in green (D, F).
Mitochondria stained with MitoTrackerTM Red CMXRos are shown in red (B, C, E, F). Laser scanning confocal microscopic merged images of (A) and (B), and (D) and (E) were
shown in (C) and (F), respectively. The results shown are representative of three independent experiments. (Adapted from Fig. 5 of [15]).
Fig. 8. 17b-HSD10 detectable only in mitochondria after the performance of a
conventional subcellular fractionation. (A) Puriﬁed human 17b-HSD10 (0.2 mg)
(lane 1), cell homogenate (lane 2), pellet (lane 3) and supernatant (lane 4); (B) the
ER fraction obtained from the altered subcellular fractionation [6,27] (lane 1) and
that obtained by use of the conventional procedure [105] (lane 2). PDI, protein
disulﬁde isomerase was used as the ER marker; COX, cytochrome C oxidase as the
mitochondria marker. (Adapted from Fig. 5 of [18]).
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the Ab-17b-HSD10 complex is about 88 nM, and oligomeric rather
than monomeric Ab would inhibit 17b-HSD10 [56]. It was claimed
that the D-loop is disordered and submerged to a large solvent
channel as shown in Fig. 2D of ref. 28. The D-loop could perhaps
binds with several Ab peptides. Nevertheless, no electron density
for Ab in the 17b-HSD10-Ab crystal was observed [28] (Supple-
mentary Materials S2). The precise oligomeric state of Ab that
binds to 17b-HSD10 has not been established. Since the inhibition
of 17b-HSD10 requires micromolar concentration of Ab [22],
aggregation of Ab is necessary to distort the NAD+ binding site [69].
4.3. Limited role of 17b-HSD10 in the production of energy
17b-HSD10 was originally identiﬁed as short chain 3-hydrox-
yacyl-CoA dehydrogenase (SCHAD) [2]. It is clear that L-3-
hydroxyacyl-CoA dehydrogenase (HAD) but not 17b-HSD10/
SCHAD plays an essential role in the mitochondrial fatty acid
b-oxidation [7,70–72]. Unfortunately, for the rationalization of
reports in literature claiming 17b-HSD10 to be a genuine alcohol
dehydrogenase and therefore designated as amyloid beta-peptide-
binding alcohol dehydrogenase (ABAD) [6,27,28,56,57], it was
asserted [56] that the catalytic mechanism of L-3-hydroxyacyl-CoA
dehydrogenase [73] is the reaction mechanism of ABAD catalyzing
the oxidation of alcohols to ketones (Scheme 1. Reduction and
oxidation of alcohols and ketones by ABAD of [56]). In fact, L-3-
hydroxyacyl-CoA dehydrogenase (HAD) and 17b-HSD10/SCHAD
are two distinct enzymes belonging to two different dehydroge-
nase families, respectively [7,70,71,74].
The conﬂation of one with the other serves to confuse the
function of 17b-HSD10 as an alcohol dehydrogenase that oxidizes
alcohols and ketone bodies to supply energy. Although this
proposition sounds plausible because of the observation that
glucose metabolism is reduced in AD brains [75], 17b-HSD10 plays
only a limited role in the production of energy, indeed. It is well
known that the oxidation of ketone bodies is catalyzed by human
D-3-hydroxybutyrate dehydrogenase [76,77] rather than by 17b-
HSD10, for which the catalytic efﬁciency for D-3-hydroxybutyrate
is negligible (Table 1). Thus, the proposition that an amyloid beta-
peptide-binding alcohol dehydrogenase is a component of the
cellular response to nutritional stress [27] sends a misleading
message.
4.4. Impairment of mitochondria due to abnormality of 17b-HSD10
It has been reported [6] that cells expressing both bAPP(V717G)
and 17b-HSD10 (ABAD/ERAB) generate toxic aldehydes, e.g., 4-
hydroxy-2-nonenal (4-HNE) whereas those expressing both bAPP
(V717G) and mutant 17b-HSD10(Y168G/K172G) do not. However,
it was later reported [78] that 17b-HSD10 can actually detoxify 4-
HNE.
17b-HSD10 is a putative intracellular mediator for Ab
neurotoxicity because it is one of dozen proteins that can bind
to Ab [30,62,79]. However, no coherent mechanistic explanation
has yet been postulated for this toxicity [80]. Mitochondrial
dysfunction and oxidative stress seem to play a key role in the
pathogenesis of AD [81]. Oxidative damage occurs early in the
brains of AD patients, and also precedes Ab deposition in an AD
mouse model [82]. The binding of Ab to 17b-HSD10 in
mitochondria might increase lipid peroxidation and reactive
oxygen species (ROS) release. ROS, in turn, would activate b-
and g-secretase and facilitate the amyloidogenic cleavage of the
amyloid-b precursor molecule. Ab would further induce free
radicals and so affect glycolysis, the tricarboxylic acid (TCA) cycle,
and the respiratory chain – especially complex IV activity –
Fig. 9. Elevated levels of mitochondrial 17b-HSD10 in brains of AD model mice. Electron micrographs of an axodendritic synapse in the hippocampus of Hsiao's bAPP
transgenic mouse (a) and of an age-matched control (b). Immunogold particles represent the location of 17b-HSD10. The large and small arrows indicate mitochondria of the
axon terminal and dendrite, respectively. An arrowhead indicates the presynaptic terminal membrane (magniﬁcation, 75,000). The results are representative of three
independent experiments. (Adapted from Fig. 4 of [26]).
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leading to reduced glucose metabolism and reduced ATP produc-
tion (Fig. 10) [79]. Opening of the mitochondrial permeability
transition pore (mPTP), the disturbance of Ca++ homeostasis, the
release of cytochrome C, and the activation of caspases would
eventually lead to DNA fragmentation and cell death. It was
reported [83] that ALLOP would directly inhibit mPTP and thus
protect neurons.
Damage to mitochondria would also cause impairment of
mitochondrial transport, imbalance of mitochondrial ﬁssion/
fusion, and abnormal mitochondria dynamics [79,84]. Mitochon-
drial function, positioning, and shape all impact brain function
and cognition [85,86]. Because synaptic mitochondria are more
vulnerable than perinuclear mitochondria, synaptic deﬁciency
occurs in the early stage of AD.
4.5. Possible target for treatment of AD
Mitochondrial 17b-HSD10 levels are signiﬁcantly increased in
the brains of individuals with AD and in an AD mouse model
[26,48]. It has also been reported that 17b-HSD10 levels are
increased in the brains of individuals with multiple sclerosis [68]
and are decreased in the brains of a Parkinson's disease (PD) mouse
model [87]. 17b-HSD10 is involved in the progression of 17b-
HSD10 deﬁciency and AD because 17b-HSD10 plays an important
role in the metabolism of neuroactive steroids, e.g., 17b-estradiol
and allopregnanolone [1,4,5,7,8,10–13,15,18,19,30,48,88] (Fig. 4).
The question of whether changes of 17b-HSD10 levels
[48,68,71,87,89] in the above-mentioned neurological disorders
and ulcerative colitis are due to alterations of HSD17B10 gene
expression remains to be answered. To date, studies on the
regulatory mechanism of HSD17B10 gene expression have been
limited [90,91]. The mechanism by which elevated levels of 17b-
HSD10 would cause the increase of ‘downstream’ proteins such as
peroxiredoxin-2 [92] and endophilin-1 [93] remains unknown.
However, what is known is that the inhibitory effect of Ab on
mtRNase P is not generated via the interaction of Ab and 17b-
HSD10 [94].
It was reported [28] that a decoy peptide synthesized according
to the D loop sequence of 17b-HSD10 (residue 92–120) would
reduce the binding of Ab to 17b-HSD10 and thus improve
mitochondrial function in an AD mouse model. However,
parenteral administration of a synthetic peptide to human may
cause immunological responses. Even if such a decoy peptide could
pass the blood-brain barrier and eventually enter into mitochon-
dria, it is not known how it might avoid degradation by
mitochondrial peptidases such as prolyl endopeptidase [95] and
insulin-degrading enzyme [96]. Thus, this decoy peptide does not
appear to be a feasible strategy for treatment of AD patients.
The etiology of late-onset AD remains elusive. An imbalance of
neuroactive steroid metabolism may have an important part to
play in neurodegenerative disorders [4,8,19]. The neuroprotective
and neurotrophic effects of 17b-estradiol and allopregnanolone
are well documented [43,97–101]. 17b-estradiol and allopregna-
nolone levels are reduced in the brains of individuals with AD
[19,44,98,102]. A proper dosing and treatment regimen will be a
key to have success in a clinical trial of the neuroactive steroid
supplementation. The inhibition of 17b-HSD10 would increase
these neuroprotective steroid levels in the brain [4,88], given that
17b-HSD10 is present in different brain regions and catalyzes the
oxidation of 17b-estradiol and allopregnanolone [4,5,10–13,48]
(Table 1 and Fig. 4). A suicide inhibitor of 17b-HSD10 has already
been tested [88] (Fig. 1). Recently, a reversible, speciﬁc steroidal
inhibitor of 17b-HSD10 was also developed [103], which may be
more suitable to the pharmaceutical industry. Approaches to
restore steroid homeostasis in AD brains, including the adjustment
of 17b-HSD10 activity, are therapeutic modalities that warrant
further exploration.
5. Concluding remarks
17b-HSD10 is the sole 17b-hydroxysteroid dehydrogenase in
mitochondria. Earlier studies indicating that 17b-HSD10 is also
localized in the plasma membrane, cytoplasm and endoplasmic
reticulum have been proved to be incorrect. Furthermore, studies
have shown that this enzyme does not possess generalized alcohol
dehydrogenase activity. Missense mutations in the HSD17B10 gene
result in 17b-HSD10 deﬁciency, an infantile neurodegenerative
disorder. Since allopregnanolone, a positive steroid modulator of
Fig. 10. Binding of Ab to 17b-HSD10 in mitochondria increases the release of reactive oxygen species ☼; reactive oxygen speciesð Þ. (Adapted from Fig. 3 of [79]).
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GABAA receptors synthesized in cytosol by 3a-HSD3 catalysis, is
inactivated by the catalysis of mitochondrial 17b-HSD10, the
imbalance of neuroactive steroid metabolism is probably a major
cause.
Elevated levels of 17b-HSD10 are present in the brains of
individuals with AD and of an AD mouse model, but the
implications of these ﬁndings have been neglected while
investigators focused on the erroneous ﬁndings of the ABAD/
ERAB studies. The rectiﬁcation of these misconceptions about
17b-HSD10 should promote more progress in this ﬁeld. Imbal-
anced neuroactive steroid metabolism appears to be associated
with mitochondrial dysfunction in brain. The restoration of
neuroactive steroid homeostasis should be a future research
direction, which may create a new approach to the treatment of
AD and other neurodegenerative disorders.
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